Inicio>>Signaling Pathways>> Neuroscience>> Neurokinin Receptor>>Fezolinetant (ESN-364)

Fezolinetant (ESN-364)

Catalog No.GC30104

Fezolinetant (ESN-364) es un antagonista del receptor de neuroquinina 3 (NK3R), utilizado para el tratamiento de los sofocos menopÁusicos.

Products are for research use only. Not for human use. We do not sell to patients.

Fezolinetant (ESN-364) Chemical Structure

Cas No.: 1629229-37-3

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
277,00 $
Disponible
1mg
101,00 $
Disponible
5mg
351,00 $
Disponible
10mg
513,00 $
Disponible
25mg
1.026,00 $
Disponible
50mg
1.638,00 $
Disponible
100mg
2.652,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Fezolinetant is an antagonist of the neurokinin 3 receptor (NK3R), used for the treatment of menopausal hot flushes.

Fezolinetant (ESN364, 1 mg/kg, iv bolus) reversibly inhibits the regular, pulsatile secretion of LH in the ovarectomized ewe. ESN364 represses the pulse pattern of LH in all treated animals. ESN364 (5 mg/kg, p.o.) lowers plasma LH, but not FSH, in the castrated monkey. ESN364 (10, 25, 50 mg/kg, orally) also blocks the LH surge and decreases ovarian hormone levels throughout the menstrual cycle in monkeys[1].

[1]. Fraser GL, et al. The NK3 Receptor Antagonist ESN364 Interrupts Pulsatile LH Secretion and Moderates Levels of Ovarian Hormones Throughout the Menstrual Cycle. Endocrinology. 2015 Nov;156(11):4214-25.

Reseñas

Review for Fezolinetant (ESN-364)

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Fezolinetant (ESN-364)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.